13.10
price up icon1.71%   0.22
pre-market  Vorhandelsmarkt:  12.99   -0.11   -0.84%
loading
Schlusskurs vom Vortag:
$12.88
Offen:
$12.88
24-Stunden-Volumen:
755.31K
Relative Volume:
1.30
Marktkapitalisierung:
$663.16M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-2.4905
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
-1.21%
1M Leistung:
+13.67%
6M Leistung:
+29.96%
1J Leistung:
+43.01%
1-Tages-Spanne:
Value
$12.82
$13.77
1-Wochen-Bereich:
Value
$12.05
$13.77
52-Wochen-Spanne:
Value
$5.035
$13.93

Regenxbio Inc Stock (RGNX) Company Profile

Name
Firmenname
Regenxbio Inc
Name
Telefon
240-552-8181
Name
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Mitarbeiter
353
Name
Twitter
@REGENXBIO
Name
Nächster Verdiensttermin
2025-08-01
Name
Neueste SEC-Einreichungen
Name
RGNX's Discussions on Twitter

Vergleichen Sie RGNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RGNX
Regenxbio Inc
13.10 652.03M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.26 117.50B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
722.83 76.06B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.56 62.53B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
916.31 56.75B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
205.04 44.10B 447.02M -1.18B -906.14M -6.1812

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-11 Herabstufung Goldman Buy → Neutral
2025-02-07 Fortgesetzt Raymond James Outperform
2024-11-15 Fortgesetzt Morgan Stanley Overweight
2024-10-10 Fortgesetzt Raymond James Outperform
2024-06-07 Eingeleitet Goldman Buy
2024-03-11 Eingeleitet H.C. Wainwright Buy
2024-03-08 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-03-06 Hochstufung Leerink Partners Market Perform → Outperform
2024-02-21 Fortgesetzt Raymond James Outperform
2023-11-01 Eingeleitet Stifel Buy
2023-06-02 Eingeleitet Robert W. Baird Outperform
2022-06-23 Eingeleitet Berenberg Buy
2021-12-15 Eingeleitet Wedbush Neutral
2021-10-19 Fortgesetzt Morgan Stanley Overweight
2021-01-06 Hochstufung Raymond James Outperform → Strong Buy
2020-12-16 Eingeleitet UBS Buy
2020-06-25 Fortgesetzt BofA/Merrill Buy
2020-05-13 Eingeleitet RBC Capital Mkts Sector Perform
2019-08-20 Hochstufung SVB Leerink Underperform → Mkt Perform
2019-06-18 Bestätigt Chardan Capital Markets Buy
2019-06-14 Fortgesetzt Raymond James Outperform
2019-06-05 Bestätigt Chardan Capital Markets Buy
2019-02-25 Hochstufung Evercore ISI In-line → Outperform
2019-02-05 Hochstufung Raymond James Outperform → Strong Buy
2018-12-17 Bestätigt Chardan Capital Markets Buy
2018-11-08 Bestätigt BofA/Merrill Neutral
2018-08-08 Bestätigt Chardan Capital Markets Buy
2018-07-23 Herabstufung BofA/Merrill Buy → Neutral
2018-07-10 Bestätigt Chardan Capital Markets Buy
2018-05-09 Bestätigt Barclays Overweight
2018-04-09 Bestätigt Chardan Capital Markets Buy
2018-03-12 Herabstufung Evercore ISI Outperform → In-line
2018-02-13 Eingeleitet Mizuho Neutral
2017-11-09 Fortgesetzt Morgan Stanley Overweight
Alle ansehen

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

pulisher
02:32 AM

What insider trading reveals about REGENXBIO Inc. stockJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser

02:32 AM
pulisher
02:07 AM

Why global investors buy REGENXBIO Inc. (RB0) stock2025 Market WrapUp & Safe Capital Allocation Plans - Newser

02:07 AM
pulisher
Dec 04, 2025

Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulus2025 Big Picture & Safe Entry Zone Identification - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Can REGENXBIO Inc. stock resist market sell offsQuarterly Profit Review & Technical Pattern Based Signals - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Is REGENXBIO Inc. stock resilient to inflationGold Moves & Fast Exit Strategy with Risk Control - Newser

Dec 04, 2025
pulisher
Dec 02, 2025

Will REGENXBIO Inc. (RB0) stock see valuation expansionWeekly Trade Analysis & Reliable Trade Execution Plans - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Will REGENXBIO Inc. (RB0) stock announce special dividend2025 Top Gainers & AI Enhanced Trading Alerts - Newser

Dec 02, 2025
pulisher
Dec 01, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

Dec 01, 2025
pulisher
Dec 01, 2025

Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights

Dec 01, 2025
pulisher
Nov 30, 2025

How (RGNX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com

Nov 30, 2025
pulisher
Nov 30, 2025

26,773 Shares in REGENXBIO Inc. $RGNX Bought by Rockefeller Capital Management L.P. - MarketBeat

Nov 30, 2025
pulisher
Nov 27, 2025

Gainers Report: Is REGENXBIO Inc. stock a contrarian buyJuly 2025 Summary & Risk Managed Trade Strategies - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 27, 2025

REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript - The Globe and Mail

Nov 27, 2025
pulisher
Nov 27, 2025

Regenxbio files $300M mixed securities shelf - MSN

Nov 27, 2025
pulisher
Nov 27, 2025

Transcript : REGENXBIO Inc. Presents at Stifel 2025 Healthcare Conference, Nov-11-2025 01 - marketscreener.com

Nov 27, 2025
pulisher
Nov 26, 2025

Regenxbio files $300M mixed shelf offering - MSN

Nov 26, 2025
pulisher
Nov 26, 2025

Regenxbio (RGNX) Files for $300M Securities Offering - GuruFocus

Nov 26, 2025
pulisher
Nov 26, 2025

Regenxbio files for mixed shelf of up to $300 millionSEC filing - marketscreener.com

Nov 26, 2025
pulisher
Nov 26, 2025

[S-3] REGENXBIO Inc. Shelf Registration Statement | RGNX SEC FilingForm S-3 - Stock Titan

Nov 26, 2025
pulisher
Nov 25, 2025

REGENXBIO to Participate in Upcoming Investor Conference - PR Newswire

Nov 25, 2025
pulisher
Nov 25, 2025

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - 富途牛牛

Nov 25, 2025
pulisher
Nov 25, 2025

REGENXBIO (Nasdaq: RGNX) Fireside Chat at Piper Sandler 37th Healthcare Conference - Stock Titan

Nov 25, 2025
pulisher
Nov 25, 2025

Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN

Nov 25, 2025
pulisher
Nov 20, 2025

RGNX S-8及美國證券交易委員會申報文件 - Yahoo 財經

Nov 20, 2025
pulisher
Nov 20, 2025

Chardan Capital Maintains Buy Rating for RGNX with $52 Price Tar - GuruFocus

Nov 20, 2025
pulisher
Nov 20, 2025

Is REGENXBIO Inc. (RB0) stock safe for risk averse investors2025 Earnings Impact & Precise Swing Trade Alerts - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Chardan Capital Maintains REGENXBIO (RGNX) Buy Recommendation - MSN

Nov 20, 2025
pulisher
Nov 20, 2025

Will REGENXBIO Inc. (RB0) stock profit from AI boomJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

How REGENXBIO Inc. stock responds to policy changes2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Visualizing REGENXBIO Inc. stock with heatmapsWeekly Trade Recap & Intraday High Probability Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Reversal indicators forming on REGENXBIO Inc. stock2025 Breakouts & Breakdowns & Intraday High Probability Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Trading Systems Reacting to (RGNX) Volatility - news.stocktradersdaily.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will REGENXBIO Inc. stock split again soonTrade Ideas & Precise Buy Zone Tips - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What data driven models say about REGENXBIO Inc.’s futurePortfolio Value Summary & Consistent Income Trade Recommendations - newser.com

Nov 19, 2025

Finanzdaten der Regenxbio Inc-Aktie (RGNX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$39.16
price down icon 1.10%
$100.48
price down icon 1.00%
$32.03
price up icon 1.10%
$95.99
price down icon 0.77%
biotechnology ONC
$331.27
price down icon 1.95%
$205.04
price down icon 0.84%
Kapitalisierung:     |  Volumen (24h):